Roflumilast Foam 0.3% Secures FDA Primary Approval to Treat Seborrheic Dermatitis

Roflumilast Foam 0.3% Secures FDA Primary Approval to Treat Seborrheic Dermatitis

Arcutis Biotherapeutics today announced the FDA approval of roflumilast foam 0.3% (ZORYVE) for the treatment of seborrheic dermatitis in patients aged 9 years and older.1 Notably, roflumilast foam 0.3% is …

Read more